Invitae has added non-invasive prenatal screening (NIPS) to the its women’s health genetic testing services. In combination with the expanded carrier screening (ECS), Invitae now offers integrated testing using the two most common prenatal genetic tests, with in-depth follow-up testing available for patients who need it. Invitae’s NIPS quickly analyzes cell-free DNA to assess whether a pregnancy (singleton or twin) is at increased risk for the three most common chromosomal disorders, including Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome) and Trisomy 13 (Patau syndrome). Microdeletion and sex chromosome analysis can be added at no additional charge. Invitae is combining its new NIPS offering with the Invitae Carrier Screen in one specimen collection kit. Invitae’s comprehensive carrier screen uses advanced sequencing to identify changes in 301 genes linked to serious genetic disorders, including cystic fibrosis (CF), spinal muscular atrophy (SMA) and many other life-threatening disorders.